This study aims at developing and evaluating reconstitutable dry suspension (RDS)\nimproved for dissolution rate, oral absorption, and convenience of use of poorly water-soluble\ncelecoxib (CXB). Micro-sized CXB particle was used to manufacture nanosuspension by using bead\nmilling and then RDS was made by spray-drying the nanosuspension with effective resuspension\nagent, dextrin. The redispersibility, morphology, particle size, crystallinity, stability, dissolution,\nand pharmacokinetic profile of the RDS were evaluated. RDS was effectively reconstituted into\nnanoparticles in 775.8 ± 11.6 nm. It was confirmed that CXB particles are reduced into needle-shape\nones in size after the bead-milling process, and the description of CXB was the same in the\nreconstituted suspension. Through the CXB crystallinity study using differential scanning calorimetry\n(DSC) and XRD analysis, it was identified that CXB has the CXB active pharmaceutical ingredient\n(API)â??s original crystallinity after the bead milling and spray-drying process. In vitro dissolution\nof RDS was higher than that of CXB powder (93% versus 28% dissolution at 30 min). Furthermore,\nRDS formulation resulted in 5.7 and 6.3-fold higher area under the curve .... and peak\nconcentration (Cmax) of CXB compared to after oral administration of CXB powder in rats. Collectively,\nour results suggest that the RDS may be a potential oral dosage formulation for CXB to improve its\nbioavailability and patient compliance.
Loading....